
How Miami's Waters Are A Lifeline For Hammerheads
An eight-year study highlights Biscayne Bay as a vital nursery and seasonal refuge for great ... More hammerhead sharks, underscoring its importance across life stages and for long-term shark conservation.
In the warm, shallow waters just off the city of Miami, is a haven for one of the ocean's most iconic yet critically endangered marine predators. Hidden beneath the skyline, among seagrass beds and mangrove shorelines, Biscayne Bay serves as a sort of 'cradle' for the great hammerhead shark, a new study from the University of Miami's Rosenstiel School of Marine, Atmospheric, and Earth Science confirms. It turns out that juvenile great hammerheads, during their most vulnerable years, rely heavily on the bay as a nursery habitat.
The great hammerhead shark (Sphyrna mokarran) is the largest species of hammerhead, easily recognized by its wide, T-shaped head and tall, curved dorsal fin. Reaching lengths of up to 20 feet (6 meters), these sharks are found in warm, coastal waters around the world. Their unique head shape enhances their ability to detect prey, especially stingrays buried in the sand, and plays a crucial role in their hunting strategy. Despite their formidable size and hunting abilities, great hammerheads are critically endangered due to overfishing, habitat loss, and their sensitivity to capture stress. They often fall victim to bycatch in commercial fisheries and are targeted for their fins. Unlike other sharks that roam vast distances, great hammerheads display strong site fidelity to certain coastal habitats, particularly during juvenile stages.
Researchers examined the feeding and habitat patterns of 62 great hammerhead sharks sampled between 2018 and 2025. Using multi-tissue stable isotope analysis (a non-lethal technique that measures the chemical 'fingerprints' left by food sources in muscle and blood plasma) the team tracked both the recent and long-term dietary habits of these animals, allowing them to understand how hammerheads use Biscayne Bay across different life stages.
What they found was striking.
'Juvenile great hammerheads show a constrained diet and habitat use, potentially feeding heavily on ... More small inshore stingrays early in life,' said Catherine Macdonald, a research associate professor in the Department of Environmental Science and Policy, and the director of the Shark Research and Conservation Program at the Rosenstiel School. 'This reliance on a narrow range of prey and habitats makes juvenile great hammerheads particularly vulnerable to human activity and environmental change.'
For their first two years of life, these young sharks depend almost entirely on the bay's inshore habitats and prey. After that, they begin venturing to coastal reefs, but they still return to the bay seasonally, usually between late spring and early summer. Some adult sharks even continue to forage in the area, showing that the bay isn't just important early on but significant throughout their entire lives.
Located in one of the most densely populated parts of Florida, Biscayne Bay has been under pressure for decades. Declining water quality, reduced freshwater inflow, and widespread physical degradation — driven by local rapid urban growth — have vastly changed the ecosystem. What was once a pristine estuary has become a hotspot for pollution, habitat loss, and stress. These changes affect all marine life in the bay, but for the young great hammerheads, they may be especially devastating. 'Juvenile great hammerheads show a constrained diet and habitat use, potentially feeding heavily
on small inshore stingrays early in life,' said Dr. Catherine Macdonald, a research associate professor in the Department of Environmental Science and Policy, and the director of the Shark Research and Conservation Program at the Rosenstiel School. 'This reliance on a narrow range of prey and habitats makes juvenile great hammerheads particularly vulnerable to human activity and environmental change.' Their limited diet and strong preference for nearshore habitats means they have fewer options if conditions deteriorate or if fishing pressure increases. And fishing pressure is a real concern, since Miami is a major destination for recreational fishing, and great hammerheads are often caught unintentionally. The species is known to be extremely sensitive to capture stress, to that point that even when released, many individuals don't survive. 'Reducing interactions with these sharks — particularly avoiding catch-and-release fishing in key nursery areas — can dramatically improve survival for this endangered species,' said researcher John Hlavin, the lead author of the study and a doctoral student in the Department of Environmental Science and Policy at the Rosenstiel School. 'If a shark is accidentally caught, the best action is a quick, in-water release, without photographs that delay the release process.' Every second the shark is out of the water decreases its odds of survival. That's why responsible fishing is critical, Hlavin continues, especially between March and July, when both juveniles and subadults are present in the bay. Avoiding catch-and-release in known nursery areas could greatly reduce mortality for this species.
The results of the study also offer valuable information for policy makers and conservationists. Stable isotope analysis revealed how tightly tied these sharks are to the bay's resources, particularly in their early life. This kind of data can be used to create spatial protections, seasonal fishing restrictions, or habitat restoration initiatives. For example, if we know juvenile hammerheads are concentrated in specific parts of Biscayne Bay in certain months, those areas can be prioritized for protection or restricted from fishing during key periods. While protecting open-ocean shark populations is challenging due to their wide-ranging nature, preserving nursery habitats like Biscayne Bay is a tangible, localized way to make a big difference.
Biscayne Bay may lie in the shadow of Miami's skyscrapers, but it's also at the heart of this species' survival. It's here, in the shallows, where these young sharks take their first bites. It's here where they learn to hunt, and where they face some of their greatest risks. The future of great hammerhead sharks may depend not just on what happens out in the deep ocean… but on what we choose to protect right here at home.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will acquire all outstanding shares of VERV for $10.50 per share in cash, aggregating to nearly $1 billion. In addition, Verve's shareholders will receive one non-tradable contingent value right (CVR) per share. This CVR entitles holders to an additional cash payment of up to $3 per share, contingent upon the first patient being dosed with Verve's lead pipeline asset, VERVE-102, for atherosclerotic cardiovascular disease (ASCVD) in a late-stage study within 10 years of the deal's closing or termination of the CVR. Including the CVR, the total potential deal value reaches approximately $1.3 billion. Post this acquisition, Lilly will add Verve's pipeline of gene therapies targeting heart diseases. This includes VERVE-102, an investigational in vivo gene-editing therapy aimed at reducing cholesterol levels. Earlier in April, Verve unveiled encouraging results from an early-stage study, which showed that a single infusion of this therapy resulted in dose-dependent reductions in blood PCSK9 protein levels and low-density lipoprotein cholesterol (LDL-C). VERVE-102 has also received Fast Track designation from the FDA, reflecting its potential to address a serious unmet need. VERV already has a partnership with LLY. Per the deal terms, Lilly has opt-in rights to co-fund development and share commercialization rights for VERVE-102. Verve is also developing another candidate, VERVE-201, targeting the ANGPTL3 protein in an early-stage study. An update on this study is expected before this year's end. A day before this announcement, the Financial Times reported that Lilly was in 'advanced talks' with Verve for a buyout. The transaction, expected to be completed in the third quarter, is subject to customary closing conditions and clearance from regulatory authorities. Verve insiders, including CEO Sekar Kathiresan and early investors, have agreed to tender their shares, representing nearly 18% of the company's outstanding stock. Following this news, shares of Verve rallied 76% in pre-market trading today. Year to date, the stock has gained 9% compared with the industry's 2% growth. Image Source: Zacks Investment Research Unlike some of its peers, Sanofi SNY and Bristol Myers BMY,which are under pressure from investors to pursue deals for new drugs, Lilly's top line continues to reach new heights. The tremendous success with GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for obesity), has made LLY the largest drugmaker with a market capitalization of more than $700 billion and its share price has crossed $800 per share. The idea behind the deal is clear — Lilly intends to strategically diversify its pipeline across therapeutic areas. Recent approvals in immunology (Omvoh and Ebglyss), oncology (Jaypirca) and neuroscience (Kisunla) highlight Lilly's intent to diversify beyond obesity and diabetes. A potential deal for Verve fits this trend. Once closed, Verve Therapeutics will be Lilly's third targeted M&A deal this year. Earlier in January, it signed a $2.5 billion deal for Scorpion Therapeutics' experimental oncology drug. Last month, Lilly announced its intent to acquire SiteOne Therapeutics in a deal valued at $1 billion to strengthen its neuroscience pipeline. Such deals suggest that Lilly's M&A strategy is selective, focusing on long-term strength across various therapeutic areas. While broader macroeconomic concerns, including Trump-era tariffs and leadership shifts at the FDA, have weighed on deal-making in 2025, Big Pharma continues to pursue strategic assets in key growth areas. This month, Sanofi announced a $9.5 billion acquisition of Blueprint Medicines to strengthen its immunology pipeline and reduce reliance on the blockbuster drug Dupixent. Through this transaction, Sanofi intends to add Ayvakit — an inhibitor of KIT and PDGFRA proteins with growing commercial traction — and several early-stage pipeline assets focused on systemic mastocytosis (SM). Sanofi expects to close this deal in the third quarter of 2025. In parallel, Bristol Myers signed a co-development and commercialization agreement with BioNTech for BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF. The deal gives Bristol Myers access to a promising oncology candidate across multiple tumor types, aligning with its strategy to offset revenue declines from legacy brands. These transactions highlight Big Pharma's continued interest in small biotechs with promising and innovative assets. Verve Therapeutics, Inc. price | Verve Therapeutics, Inc. Quote Verve currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Verve Therapeutics, Inc. (VERV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research


Forbes
an hour ago
- Forbes
NASA Spacecraft ‘Touches Sun' For Final Time In Defining Moment For Humankind
The heavily armored Parker Solar Probe has traveled to within just 3.86 million miles (6.1 million kilometers) of the sun's surface — what NASA calls 'hyper close.' It's the third and final time it has performed the feat, following similar achievements on Dec. 24, 2024, and March 22, 2025. Parker launched on Aug. 12, 2018, and has since conducted 23 perihelions — close passes — of the sun, getting to within 3.86 million miles (6.1 million kilometers) twice before today's repeat performnce. For scale, that's four yards from the end zone if the distance between Earth and the sun was the length of an American football field, according to mission scientists. During this final perihelion of the mission, the probe will be traveling at around 430,000 miles per hour (690,000 kilometers per hour). According to NASA, that's fast enough to get from Philadelphia to Washington, D.C., in a single second. Perihelion 24 also sees it forced to withstand temperatures of 1,600 to 1,700 degrees Fahrenheit (870 to 930 degrees Celsius). Its only armor against both temperature and extreme ultraviolet radiation is a carbon composite shield. Parker is in a highly elliptical orbit, which takes 88 days but allows it to occasionally swoop particularly close to the sun. One of the main objectives of the mission is to understand why the sun's corona, its outer atmosphere, is a million times hotter than the photosphere, its surface. The corona is where the solar wind originates from, so solar physicists must understand it better if they are to forecast space weather more accurately. That's important because the state of the solar wind — a stream of charged particles interacting with the Earth's atmosphere — can damage satellites and harm astronauts, as well as cause Northern Lights. The latter half of Parker's mission has coincided with the peak of Solar Cycle 25, the current 11-year-long cycle of the sun, during which our star experiences a waxing and waning of magnetic activity. A study published on June 3 used data from Parker while flying close to the sun, reveal a new source for energetic particles in the solar corona. The mechanism, called magnetic reconnection, heats the solar atmosphere, accelerating solar wind particles. Magnetic reconnection — when magnetic field lines converge, break apart and reconnect in an explosive physical process — is responsible for powerful solar events, such as solar flares and coronal mass ejections. 'We've seen how magnetic reconnection behaves near Earth, but Parker has now shown how potent it is near the sun, where magnetic fields are significantly stronger,' said Dr. Mihir Desai, lead author and a scientist at the Southwest Research Institute in San Antonio, Texas. Parker isn't going anywhere. Locked in the orbit of the sun, it will continue to loop around our star. However, it was gravity assists at Venus that gave the spacecraft enough momentum to get so close to the sun. No, it's within the orbit of Venus, that opportunity is lost, so it won't be able to reach any closer to the sun than it already has done. According to Live Science, the spacecraft's thrusters will eventually run out of fuel, and it will burn up, though its heat shield may remain in orbit for thousands of years.

Associated Press
an hour ago
- Associated Press
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it
WASHINGTON (AP) — The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called lenacapavir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. 'This really has the possibility of ending HIV transmission,' said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research. Condoms help guard against HIV infection if used properly but what's called PrEP — regularly using preventive medicines such as the daily pills or a different shot given every two months — is increasingly important. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills. But upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said 'gaping holes in the system' in the U.S. and globally 'are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' twice a year to keep up their protection. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. It's given as two injections under the skin of the abdomen, leaving a small 'depot' of medication to slowly absorb into the body. People must test negative for HIV before getting their twice-a-year dose, Gilead warned. It only prevents HIV transmission — it doesn't block other sexually transmitted diseases. Some researchers who helped test the shot advise cold packs to counter injection-site pain. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' Gilead said the U.S. list price, meaning before insurance, is $28,218 a year, which it called similar to some other PrEP options. The company said it anticipated insurance coverage but also has some financial assistance programs. Most private insurers are supposed to cover PrEP options without a co-pay although the Supreme Court is considering a case that could overturn that requirement. Congress also is considering huge cuts to Medicaid. And while community health centers still are an option, the Trump administration has largely dismantled HIV prevention work at the Centers for Disease Control and Prevention that would normally get the message to vulnerable populations who'd qualify for the shot, said Carl Schmid of the nonprofit HIV+Hepatitis Policy Institute. Schmid worries the shot won't meet its potential because 'we're basically pulling the rug out of HIV prevention and testing and outreach programs.' Gilead also has applications pending for the twice-yearly shot in other countries. Last fall, the company signed agreements with six generic drug makers to produce low-cost versions of the shot for 120 poor countries mostly in Africa, Southeast Asia and the Caribbean. Gilead plans to make enough shots to supply 2 million people in those countries, at no profit, until the generics are available, said company senior vice president Dr. Jared Baeten. Winnie Byanyima, executive director of UNAIDS, said in a statement the price is still too high. If it's unaffordable, she said, 'it will change nothing.' And HIV experts worry the arrangements Gilead has made to reduce costs in some countries leave out middle-income countries like some in Latin America. 'Everyone in every country who's at risk of HIV needs access to PrEP,' said Dr. Gordon Crofoot of Houston, who helped lead the study in men. 'We need to get easier access to PrEP that's highly effective like this is.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.